Cargando…

Review of health-related quality of life data in multiple myeloma patients treated with novel agents

In multiple myeloma (MM), health-related quality of life (HRQoL) data is becoming increasingly important, owing to improved survival outcomes and the impact of treatment-related toxicity on HRQoL. Researchers are more frequently including HRQoL assessments in clinical trials, but analysis and report...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sonneveld, P, Verelst, S G, Lewis, P, Gray-Schopfer, V, Hutchings, A, Nixon, A, Petrucci, M T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806249/ https://www.ncbi.nlm.nih.gov/pubmed/23783393 http://dx.doi.org/10.1038/leu.2013.185

Ejemplares similares

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment
por: Leleu, X, et al.
Publicado: (2017)

Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma
por: Bennink, M. Christine, et al.
Publicado: (2022)

Individual quality of life in patients with multiple myeloma
por: Dürner, Julia, et al.
Publicado: (2013)

Quality of Life and Supportive Care in Multiple Myeloma
por: Cömert, Melda, et al.
Publicado: (2013)

Impact of quality of response on survival outcomes among multiple myeloma patients treated with novel agents – a retrospective analysis
por: Ćojbašić, Irena, et al.
Publicado: (2022)

Multiple Myeloma with Hyperammonemia Treated with Novel Agents: A Case Series of Three Patients
por: Nakamura, Hajime, et al.
Publicado: (2022)

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2018)

Innovative Agents in Multiple Myeloma
por: Faiman, Beth, et al.
Publicado: (2014)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
por: Ludwig, Heinz, et al.
Publicado: (2010)

Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
por: Dimopoulos, Meletios A., et al.
Publicado: (2014)

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Bone-targeted agents in multiple myeloma
por: Nishida, Hiroko
Publicado: (2018)

Emerging agents and regimens for multiple myeloma
por: Yang, Yang, et al.
Publicado: (2020)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS)
por: Verelst, Silvia G.R., et al.
Publicado: (2018)

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
por: Chim, C S, et al.
Publicado: (2018)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma
por: O’Donnell, Elizabeth K., et al.
Publicado: (2022)

Multiple myeloma with t(11;14): impact of novel agents on outcome
por: Puertas, Borja, et al.
Publicado: (2023)

P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV)
por: Seefat, M.R., et al.
Publicado: (2023)

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents
por: Mina, Roberto, et al.
Publicado: (2020)

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations()
por: Lopez, Aurelio, et al.
Publicado: (2015)

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
por: Chim, C. S., et al.
Publicado: (2019)

Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2023)

Targeting the Microenvironment for Treating Multiple Myeloma
por: Neumeister, Peter, et al.
Publicado: (2022)

B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS
por: Wester, R., et al.
Publicado: (2023)

New investigational drugs with single-agent activity in multiple myeloma
por: Rajan, A M, et al.
Publicado: (2016)

Front line treatment of elderly multiple myeloma in the era of novel agents
por: Venon, Marie-Dominique, et al.
Publicado: (2009)

Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies
por: Larsen, Jeremy T., et al.
Publicado: (2015)

Novel agents in the treatment of multiple myeloma: a review about the future
por: Naymagon, Leonard, et al.
Publicado: (2016)

Patient-Reported Outcomes and Assessment of Quality of Life: A Focus on Multiple Myeloma
por: Fragola, Maryann
Publicado: (2020)

Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
por: Delforge, Michel, et al.
Publicado: (2022)

Quality of life assessment & out-of-pocket expenditure in multiple myeloma: An observational study
por: Mathew, Anisha, et al.
Publicado: (2021)

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
por: Terpos, Evangelos, et al.
Publicado: (2013)

Kinase inhibitors as potential agents in the treatment of multiple myeloma
por: Abramson, Hanley N.
Publicado: (2016)

High Hospital-related Costs at the End-of-life in Patients With Multiple Myeloma: A Single-center Study
por: Bennink, Christine, et al.
Publicado: (2023)

The Anti-CD38 Antibody Therapy in Multiple Myeloma
por: Petrucci, Maria Teresa, et al.
Publicado: (2019)

Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art
por: Martino, Massimo, et al.
Publicado: (2020)

Emerging drugs and combinations to treat multiple myeloma
por: Larocca, Alessandra, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u5qik9u8rvsfmigj4hklijq16v